19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Amiloride selectively inhibits the urokinase-type plasminogen activator.

      Febs Letters
      Amiloride, pharmacology, Animals, Humans, In Vitro Techniques, Kinetics, Plasminogen Activators, antagonists & inhibitors, Plasminogen Inactivators, Protease Inhibitors, metabolism, Sodium, Tissue Plasminogen Activator, Urokinase-Type Plasminogen Activator

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The diuretic drug amiloride, an inhibitor of Na+ uptake, competitively inhibits the catalytic activity of the urokinase-type plasminogen activator (u-PA), with a Ki of 7 X 10(-6) M. Generation of plasmin, cleavage of peptide substrates, and interaction of u-PA with a specific macromolecular proteinase inhibitor are all prevented in the presence of the drug. In contrast, amiloride does not affect the activity of either tissue-type plasminogen activator, plasmin, plasma kallikrein or thrombin. The inhibition of u-PA by amiloride may be related to the previously reported inhibition of u-PA-type enzymes by Na+. Amiloride or related compounds could prove useful in selectively controlling u-PA-catalyzed extracellular proteolysis.

          Related collections

          Author and article information

          Comments

          Comment on this article

          Related Documents Log